Trial Profile
A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Phaeochromocytoma; Renal cancer; Solid tumours; Thyroid cancer
- Focus Therapeutic Use
- 09 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 09 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Actual patient number is 37 according to ClinicalTrials.gov.